And I think something that comes up very commonly for many of us are patients who are pursuing compounded agents or compounded GLP-1 receptor agonists for various reasons, and that will be the focus of our discussion today
Buyer Takeaway: Compounded injectable GLP-1s require self-measurement from a vial - a meaningfully different administration process from brand-name pre-filled auto-injectors
The abundance of blood metabolites at 10 hr was categorized as H (high), M (medium), or L (low) 6

is a principal investigator in the following: Restore-Life VNS registry study funded by LivaNova, ESKETINTRD3004: An open-label, long-term, safety and efficacy study of intranasal esketamine in treatment-resistant depression, The effects of psilocybin on cognitive function in healthy participants, The safety and efficacy of psilocybin in participants with treatment-resistant depression (P-TRD), A double-blind, randomized, parallel-group study with quetiapine extended release as comparator to evaluate the efficacy and safety of seltorexant 20 mg as adjunctive therapy to antidepressants in adult and elderly patients with major depressive disorder with insomnia symptoms who have responded inadequately to antidepressant therapy (Janssen), An open-label, long-term, safety and efficacy study of aticaprant as adjunctive therapy in adult and elderly participants with major depressive disorder (MDD) (Janssen), A randomized, double-blind, multicenter, parallel-group, placebo-controlled study to evaluate the efficacy, safety, and tolerability of aticaprant 10 mg as adjunctive therapy in adult participants with major depressive disorder (MDD) with moderate-to-severe anhedonia and inadequate response to current antidepressant therapy, A study of disease characteristics and real-life standard of care effectiveness in patients with major depressive disorder (MDD) with anhedonia and inadequate response to current antidepressant therapy including an SSRI or SNR (Janssen) as well as UK Chief Investigator for Compass (COMP006 & COMP007 studies) and Novartis MDD study (MIJ821A12201)

Just as results increase with a higher dose, so do potential side effects